Which Alzheimer’s drug trials are expected to release results in 2026?

Multiple companies are set to share data from Phase 3 trials including Bristol Myers Squibb, Cognito Therapeutics, and Eli Lilly. Bristol Myers Squibb’s KarXT’s is being tested to treatAlzheimer’s psychosis and cognitive symptoms., Cognito Therapeutics’ SPECTRIS headset uses flickering lights and sounds to stimulate the brain in early Alzheimer’s. Lilly is expected to present some data from its next-generation anti-amyloid drug as well.